Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.
Adjusted EPS was $2.42 compared to $2.18 in prior-year quarter, beating the consensus of $2.31. For FY24, MMM sees adjusted sales growth of 0.25% to 2.25% and adjusted EPS of $9.35 – $9.75 vs. $9.82 estimate.
3M shares dipped 12.5% to $94.54 on Tuesday.
Here are some other stocks moving in today's mid-day session.
Gainers
FaZe Holdings Inc.. (NASDAQ: FAZE) shares climbed 63.6% to $0.2528. FaZe and Rollbit announced a new multi-million dollar esports sponsorship deal.
Rail Vision Ltd. (NASDAQ: RVSN) jumped 57.4% to $3.5420. Rail Vision recently announced its Main Line system has successfully obtained formal certifications for critical European Union railway standards.
Nuvve Holding Corp. (NASDAQ: NVVE) shares surged 44.6% to $4.31. Nuvve won a $16 million project for Fresno Economic Opportunities Commission's 50-shuttle fleet.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) gained 29% to $1.4701. Ensysce Biosciences said that the FDA has granted Breakthrough Therapy Designation for PF614-MPAR.
Bit Brother Limited (NASDAQ: BETS) surged 26% to $3.97 after the company requested immediate withdrawal of its Registration Statement on Form F-3 filed with the SEC on Jan. 16, 2024.
Gamer Pakistan Inc. (NASDAQ: GPAK) shares climbed 21.8% to $0.3180 after falling more than 9% on Monday.
Sensus Healthcare, Inc. (NASDAQ: SRTS) gained 21.4% to $3.23. Sensus Healthcare announced preliminary fourth-quarter revenue of $12 million and 2023 revenue exceeding $23 million.
Catheter Precision, Inc. (NYSE: VTAK) rose 20.8% to $0.58. Catheter Precision Director, Executive Chairman and CEO David A Jenkins acquired a total of 16,940 shares at an average price of $0.42.
Solid Power, Inc. (NASDAQ: SLDP) rose 20.5% to $1.41. Solid Power announced a $50 million share repurchase authorization.
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) gained 20.3% to $0.9999. Unicycive Therapeutics ...
Benzinga
